Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: Results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD)

International Angiology

Volumn 29, Issue 2 SUPPL. 1, 2010, Pages 2-13

  Shigematsu, H ^a   Nishibe, T ^a,b   Obitsu, Y ^a   Matsuzaki, K ^c   Ishida, A ^d,e   Miyata, T ^f   Shindo, S ^a,g   Hida, K ^h   Ohta, T ⁱ   Ando, M ^b   Kawasaki, T ^j   Yasugi, T ^k   Matsumoto, T ^l  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^d CHIBA UNIVERSITY HOSPITAL   (Japan)

^e JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g UNIVERSITY OF YAMANASHI   (Japan)

^h KANAZAWA MEDICAL UNIVERSITY   (Japan)

ⁱ AICHI MEDICAL UNIVERSITY   (Japan)

^j OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l KYUSHU UNIVERSITY   (Japan)

more..

Author keywords

Aspirin; Beraprost; Cardiovascular diseases; Cilostazol; Peripheral arterial diseases, drug therapy

Indexed keywords

ACETYLSALICYLIC ACID; BERAPROST; CILOSTAZOL;

ADULT; AGED; ARTERY DISEASE; ARTICLE; BRAIN DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COHORT ANALYSIS; DIALYSIS; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; FOLLOW UP; HEART DEATH; HEART DISEASE; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LEG; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SENESCENCE; TREATMENT OUTCOME; VASCULAR SURGERY;

ADULT; AGED; AGED, 80 AND OVER; ANKLE BRACHIAL INDEX; ASPIRIN; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; EPOPROSTENOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SOCIETIES, MEDICAL; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; VASCULAR SURGICAL PROCEDURES; VASODILATOR AGENTS;

EID: 77953257447     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71:510-5.
2. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation 1995;91:1472-9.
3. Selvin E, Erlinger TP: Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004;110:738-43.
4. H Aramoto, H Oshiro, H shigematsu K Yasuda, T Nishibe, Y Nimura, et al. Survey on Quality of life(QOL) in patients with Arteriosclerosis obliterans(ASO). J Jpn Coll Angiol 2003;43:9-13.
5. Schneider JR, McHorney CA, Malenka DJ, McDaniel MD, Walsh DB, Cronenwett JL. Functional health and well-being in patients with severe atherosclerotic peripheral vascular occlusive disease. Ann Vasc Surg 1993;7:419-28.
6. Eagle KA, Rihal CS, Foster ED, Mickel MC, Gersh BJ. Long-term survival in patients with coronary artery disease: importance of peripheral vascular disease. The Coronary Artery Surgery Study (CASS) Investigators. J Am Coll Cardiol 1994;23:1091-5.
7. Ohta T, Kato T, Kazui H, Koudo M, Tsuchioka H, Shionoya S. The prognosis of intermittent claudication. J Jpn Surg Soc 1987;90:615-21.
8. Eickhoff JH. Survival after arterial reconstruction in arteriosclerosis obliterans of the lower limbs. Acta Chir Scand 1978;144:17-20. (Pubitemid 8327465)
9. Sladen JG, Gilmour JL. Fate of claudicans after femoropopliteal vein bypass: Prospective, long-term follow-up of 100 patients. Can J Surg 1985;28:401-4.
10. Kobayashi M, Shindo S, Kubota K, Kojima A, Ishimoto T, Iyori K et al. Causes of late mortality in patients with disabiling intermittent claudication. Jpn Circ J 2000;64 925-7.
11. Trans-Atlantic Inter-Society Consensus (TASC) Working Group: Management of peripheral arterial disease (PAD). Eur J Vasc Endovasc Surg 2000;19 (Suppl A): Si-xxviii. S1-S250.
12. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007;33(Suppl 1):S1-75.
13. Nishibe T, Muto A, Kondo Y, Ando M. Pharmacotherapy for arteriosclerosis obliterans. Jpn J Vasc Surg 2005;14:63-72.
14. Matsubara J, Shiiya N, Ishida A, Miyata T, Shigematsu H, Obitsu Y, et al. Current status of medication therapy for arteriosclerosis obliterans (ASO) in university hospital in Japan. J Jpn Coll Angiol 2007;47:153-62.
15. Lièvre M, Morand S, Besse B, Fiessinger JN, Boissel JP l: Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. Circulation. 2000; 102: 426-431.
16. Mohler ER 3rd, Hiatt WR, Olin JW, Wade M, Jeffs R, Hirsch AT. Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial. J Am Coll Cardiol 2003;41:1679-86.
17. Origasa H, Ikeda Y, Shimada K, Shigematsu H. Oral berprost sodium as a prostaglandin 12 analogue for vascuar events in patients with peripheral arterial disease: mata-analysis of two placebo-controlled randomized trials?Jpn J Pharmacoepidemiol 2004;9:45-51.
18. Miyazaki K, Nishibe T, Sata F, Miyazaki YI, Kudo FA, Flores J et al. Prosthetic grafts for above-knee femoropopliteal bypass. A multicenter retrospective study of 564 grafts. Int Angiol 2002;21:145-51.
19. Thompson PD, Zimet R, Forbes WP, Zhang PL. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002;90:1314-9.
20. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
21. Yamazaki T, Goto S, Shigematsu H, Shimada K, Uchiyama S, Nagai R et al. Japan Thrombosis Registry for Atrial Fibrillation, Coronary or Cerebrovascular Event. Jpn J Stroke 2006;28:535-7.
22. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL et al. REACH Registry Investigators: International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-9.
23. Yamazaki T, Goto S, Shigematsu H, Shimada K, Uchiyama S, Nagai R et al. Prevalence, awareness and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan. Circ J 2007;71:995-1003.
24. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence or asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991;20:384-92.
25. Kumakura H, Kanai H, Araki Y, Syu K, Ito T, Tojima S et al. Survival rate and long-term results of treatments in patients with peripheral arterial disease - endovascular treatment, bypass surgery and medical treatment. J Jpn Coll Angiol 2006;46:565-70.
26. Steg PG, Bhatt DL, Wilson PW, D'Agostino R Sr, Ohman EM, Röther JJ et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007;297:1197-206.
27. Wattanakit K, Folsom AR, Selvin E, Coresh J, Hirsch AT, Weatherley BD. Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol 2007;18:629-36.
28. Liew YP, Bartholomew JR, Demirjian S, Michaels J, Schreiber MJ Jr. Combined effect of chronic kidney disease and peripheral arterial disease on all-cause mortality in a high-risk population. Clin J Am Soc Nephrol. 2008; 3: 1084-1089.
29. Brown J, Lethaby A, Maxwell H, Wawrzyniak AJ, Prins MH:Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev. 2008:CD000535.
30. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;30:1849-60.